United TherapeuticsUTHR
Oncology1 cited findings · profile updated 2026-08-20
529.14 USDnot live — refreshed daily
1 Day
+2.1%
5 Day
+3.4%
1 Month
-1.2%
3 Month
-6.2%
About United Therapeutics
United Therapeutics (UTHR) has engaged in oncology research, as evidenced by regulatory submissions. One notable instance is an Investigational New Drug (IND) submission, identified as IND 110494.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| IND submission | 110494 | UNITED THERAP — Unituxin FDA Summary Review (NDA/BLA 125516, 2015), p.9 |
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →